chloroquine and derivatives - versus placebo - for COVID 19 hospitalized   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.89 [0.54, 1.46]< 10%3 studies (3/-)67.9 %some concernnot evaluable moderatecrucial-
clinical improvement 1.02 [0.73, 1.42]> 10%1 study (1/-)54.6 %lownot evaluable highimportant-
clinical worsening 1.80 [0.62, 5.21]< 10%1 study (1/-)13.9 %some concernnot evaluable moderateimportant-
death or ventilation 1.12 [0.45, 2.79]< 10%1 study (1/-)40.4 %some concernnot evaluable moderateimportant-

-- safety endpoints 00

adverse events 1.20 [0.70, 2.08]< 10%2 studies (2/-)25.4 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 95,94,90,91 95